Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 7/20 | 0.42 |
| ▸ | CPB1 | P15086 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL201190 | 1.00 | CPB2 (0.42) | CPB2CPB1SMN1; SMN2ALDH1A1CYP1A2 | |
| SCHEMBL7738753 | 0.88 | CPB2 (0.49) | CPB2CPB1SMN1; SMN2ALDH1A1CYP1A2 | |
| SCHEMBL7738755 | 0.88 | CPB2 (0.49) | CPB2CPB1SMN1; SMN2ALDH1A1CYP1A2 | |
| SCHEMBL17484674 | 0.88 | CPB2 (0.32) | CPB2CPB1 | |
| SCHEMBL30700154 | 0.87 | CPB2 (0.34) | CPB2CPB1 | |
| SCHEMBL4305378 | 0.87 | CPB2 (0.32) | CPB2CPB1 | |
| SCHEMBL147911 | 0.86 | CPB2 (0.38) | CPB2CPB1SMN1; SMN2ALDH1A1CYP1A2 | |
| SCHEMBL7074055 | 0.86 | CPB2 (0.40) | CPB2CPB1SMN1; SMN2ALDH1A1CYP1A2 | |
| SCHEMBL28558505 | 0.86 | CPB2 (0.38) | CPB2CPB1SMN1; SMN2ALDH1A1CYP1A2 | |
| SCHEMBL10777853 | 0.86 | CPB2 (0.40) | CPB2CPB1SMN1; SMN2ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119925300-A | IL 12 mRNA lipid nanoparticle and preparation method and application thereof | 杭州宜生医药科技发展有限公司 | 2025-05-06 | — | — | CN | claimed |
| WO-2023183247-A2 | METHODS AND COMPOSITIONS FOR SUPPRESSION OF BIOGENIC AMINES PRODUCED BY THE GUT MICROBIOME | CEDARS-SINAI MEDICAL CENTER (US) | 2023-09-28 | — | — | WO | claimed |
| EP-4401745-A1 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING NEURODEGENERATIVE DISEASES | MarvelBiome, Inc. (US) | 2024-07-24 | — | — | EP | disclosed |
| US-20240182532-A1 | MICROPEPTIDES AND USES THEREOF | FUNDACIÓ PRIVADA INSTITUT D'INVESTIGACIÓ ONCOLÒGICA DE VALL HEBRON (ES) | 2024-06-06 | — | — | US | disclosed |
| CN-117665155-A | Gastric cancer blood metabolism biomarker and screening method | 浙江省肿瘤医院 | 2024-03-08 | — | — | CN | disclosed |
| US-11858972-B2 | Micropeptides and uses thereof | FUNDACIÓ PRIVADA INSTITUT D'INVESTIGACIÓ ONCOLÒGICA DE VALL HEBRON (ES) | 2024-01-02 | — | — | US | disclosed |
| US-20230183253-A1 | NANOMATERIAL COMPOSITIONS, SYNTHESIS, AND ASSEMBLY | RHODE ISLAND HOSPITAL | 2023-06-15 | — | — | US | disclosed |
| WO-2023044076-A1 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING NEURODEGENERATIVE DISEASES | MarvelBiome, Inc. (US) | 2023-03-23 | — | — | WO | disclosed |
| US-20220120732-A1 | TREATMENT OF DISEASES WITH MULTIMERIC PEPTIDES | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2022-04-21 | — | — | US | disclosed |
| CN-114375333-A | Compositions comprising a propeptide of lysyl oxidase and uses thereof | 耶达研究及发展有限公司 | 2022-04-19 | — | — | CN | disclosed |
| US-20220049236-A1 | COMPOSITIONS COMPRISING THE PROPEPTIDE OF LYSYL OXIDASE AND USES THEREOF | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2022-02-17 | — | — | US | disclosed |
| EP-1408995-A1 | MODULATING SERUM AMYLOID A INTERACTION WITH TANIS AND AGENTS USEFUL FOR SAME | Autogen Research Pty. Ltd. (AU) | 2004-04-21 | — | — | EP | disclosed |
| WO-2003061606-A1 | GLASS-IONOMER CEMENTS CONTAINING AMINO ACIDS | UAB RESEARCH FOUNDATION (US) | 2003-07-31 | — | — | WO | disclosed |
| WO-2003000273-A1 | MODULATING SERUM AMYLOID A INTERACTION WITH TANIS AND AGENTS USEFUL FOR SAME | AUTOGEN RESEARCH PTY. LTD. (AU) | 2003-01-03 | — | — | WO | disclosed |
| WO-2002098348-A2 | GLP-1 FORMULATIONS WITH PROTRACTED TIME ACTION | ELI LILLY AND COMPANY (US) | 2002-12-12 | — | — | WO | disclosed |
| US-5614510-A | AMMONIUM SALTS | PERSTORP AB (SE) | 1997-03-25 | — | — | US | disclosed |
| EP-0627922-A1 | A PHARMACEUTICAL COMPOSITION WITH IMPROVED BIOAVAILABILITY OF INOSITOL PHOSPHATE | PERSTORP AB (SE) | 1994-12-14 | — | — | EP | disclosed |
| WO-1993016705-A1 | A PHARMACEUTICAL COMPOSITION WITH IMPROVED BIOAVAILABILITY OF INOSITOL PHOSPHATE | PERSTORP AB (SE) | 1993-09-02 | — | — | WO | disclosed |
| WO-1991003562-A1 | IMMUNOGLOBULIN-BINDING POLYPEPTIDES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1991-03-21 | — | — | WO | disclosed |
| EP-0129254-A2 | Process for the preparation of N-tau-substituted histidine derivatives, the N-tau-substituted histidine derivatives and their use | DIAMALT AKTIENGESELLSCHAFT (DE) | 1984-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183253-A1 | NANOMATERIAL COMPOSITIONS, SYNTHESIS, AND ASSEMBLY | POLRMT, NT5C3B, CHMP4B | CPB2 1711/4885CPB1 2181/4885SMN1; SMN2 292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.